188 related articles for article (PubMed ID: 23809043)
1. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
Lewis KA; Goldyn AK; West KW; Eugster EA
J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043
[TBL] [Abstract][Full Text] [Related]
2. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.
Lewis KA; Eugster EA
J Pediatr; 2013 Mar; 162(3):562-5. PubMed ID: 23040793
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA
J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
5. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
6. Experience with the Histrelin Implant in Pediatric Patients.
Eugster EA
Endocr Dev; 2016; 30():54-9. PubMed ID: 26683629
[TBL] [Abstract][Full Text] [Related]
7. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028
[TBL] [Abstract][Full Text] [Related]
8. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
9. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.
Pescovitz OH; Comite F; Hench K; Barnes K; McNemar A; Foster C; Kenigsberg D; Loriaux DL; Cutler GB
J Pediatr; 1986 Jan; 108(1):47-54. PubMed ID: 3080571
[TBL] [Abstract][Full Text] [Related]
10. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty.
Ray LA; Eckert GJ; Eugster EA
J Pediatr Endocrinol Metab; 2023 Mar; 36(3):309-312. PubMed ID: 36625262
[TBL] [Abstract][Full Text] [Related]
11. Histrelin for central precocious puberty-a single surgeon experience.
Rosati S; Maarouf R; Brown K; Poppe M; Parrish D; Haynes J; Lanning D
J Surg Res; 2015 Oct; 198(2):355-9. PubMed ID: 25899147
[TBL] [Abstract][Full Text] [Related]
12. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
13. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database.
Silverman LA; Han X; Huang H; Near AM; Hu Y
J Pediatr Endocrinol Metab; 2021 Aug; 34(8):961-969. PubMed ID: 34147047
[TBL] [Abstract][Full Text] [Related]
15. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
[TBL] [Abstract][Full Text] [Related]
16. Resumption of puberty in girls and boys following removal of the histrelin implant.
Fisher MM; Lemay D; Eugster EA
J Pediatr; 2014 Apr; 164(4):912-916.e1. PubMed ID: 24433825
[TBL] [Abstract][Full Text] [Related]
17. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
[TBL] [Abstract][Full Text] [Related]
18. [Effects of HPGA suppression on predicted adult height in girls with central precocious puberty].
Tao YH; Zeng BH; Sharif N
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Oct; 17(10):1093-7. PubMed ID: 26483231
[TBL] [Abstract][Full Text] [Related]
19. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls.
Houk CP; Kunselman AR; Lee PA
Pediatrics; 2009 Jun; 123(6):e1059-63. PubMed ID: 19482738
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of basal LH in monitoring central precocious puberty treatment in girls.
Calcaterra V; De Filippo G; Albertini R; Rendina D; Messini B; Monti CM; Bozzola E; Villani A; Bozzola M
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):45-50. PubMed ID: 33189082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
